The combination of Ipamorelin and CJC-1295 (no-DAC) is widely recognised as the gold standard GH secretagogue stack in peptide research. By pairing a selective ghrelin mimetic with a GHRH analogue, researchers can study amplified, pulsatile GH release through two complementary receptor pathways — without disrupting the somatostatin brake that regulates natural GH feedback. Peptide Central also stocks a pre-blended CJC-Ipamorelin blend for researchers who prefer a single vial.
The Two Pathways: GHRH and Ghrelin
Growth hormone release from the anterior pituitary is regulated by two primary stimulatory signals: GHRH (growth hormone-releasing hormone) from the hypothalamus, and ghrelin acting at the GHS-R1a (growth hormone secretagogue receptor 1a). These are distinct receptor systems that synergise — activation of both simultaneously produces GH pulses significantly larger than either pathway alone.
CJC-1295 (no-DAC) is a GHRH analogue that binds the pituitary GHRH receptor, mimicking the hypothalamic GHRH signal. Its half-life of approximately 30 minutes produces a clean pulse that closely mirrors the natural GHRH pulse shape. It has no DAC (Drug Affinity Complex) modification, so it does not bind to albumin for extended release — this is deliberate in pulsatile research protocols.
Ipamorelin is a pentapeptide ghrelin mimetic — selective for the GHS-R1a receptor. Its key research advantage is selectivity: unlike older GHRPs (GHRP-2, GHRP-6), Ipamorelin does not meaningfully stimulate cortisol or prolactin release at research doses, making it the cleanest tool for studying GH secretion through the ghrelin axis.
Why This Stack Works: Synergy Across Receptor Systems
When CJC-1295 (no-DAC) and Ipamorelin are administered simultaneously, they act on different receptor populations within the same somatotroph cell. GHRH receptor activation primes the cell and drives cAMP-mediated GH synthesis. GHS-R1a activation (Ipamorelin) operates through a separate Gq/phospholipase C pathway that increases intracellular calcium. The convergence of these two signals on the somatotroph produces a GH pulse substantially greater than additive — true pharmacological synergy.
Critically, neither compound suppresses somatostatin feedback. The result is amplified GH pulses that remain within a pulsatile architecture, preserving the on/off rhythm that the GH axis depends on for normal downstream signalling.
Research Applications
Body Recomposition
Elevated GH pulses drive lipolysis in adipose tissue while supporting nitrogen retention in muscle. The GH/IGF-1 axis governs substrate partitioning — directing calories toward lean tissue synthesis and away from fat storage. The Ipamorelin/CJC stack is frequently used in body recomposition research for this reason.
Recovery and Connective Tissue
GH and IGF-1 are critical mediators of connective tissue repair — tendons, ligaments, and cartilage are all responsive to GH axis stimulation. Researchers studying recovery from musculoskeletal stress use this stack as a baseline GH support protocol, sometimes alongside direct healing peptides.
Anti-Aging and Sleep Quality
Endogenous GH secretion declines significantly with age, with the largest pulses occurring during deep (slow-wave) sleep. Restoring youthful GH pulse amplitude is a key vector in longevity research. Ipamorelin administered before sleep specifically targets the sleep-associated GH pulse.
Dosage Protocol
Ipamorelin: 200–300 mcg per injection
CJC-1295 (no-DAC): 100–200 mcg per injection
Frequency: 2–3 times daily; most common is morning (fasted) and 30–60 minutes before sleep
Administration: Both are reconstituted separately and injected subcutaneously, either in the same syringe draw or as separate injections
Use the BAC Water Calculator to work out concentration and IU draw for each vial independently before combining in a syringe or injecting separately.
Pre-Blended Option
For simplified protocols, Peptide Central stocks a CJC-Ipamorelin pre-blend — both peptides in a single vial at a 1:1 ratio. This reduces injection count and simplifies reconstitution for researchers who have confirmed their individual tolerances and are working at fixed ratio doses.
Where to Buy Ipamorelin and CJC-1295 in India
Peptide Central stocks Ipamorelin, CJC-1295 (no-DAC), and the CJC-Ipamorelin blend at 99% purity, HPLC-verified with COA included. Pan-India delivery, COD available.
Frequently Asked Questions
Why is CJC-1295 no-DAC preferred over CJC-1295 with DAC?
CJC-1295 with DAC (Drug Affinity Complex) binds to serum albumin, extending its half-life to days and producing a continuous GH elevation rather than a pulse. Most researchers prefer the no-DAC version because it produces a discrete pulse that respects the pulsatile architecture of the GH axis and pairs cleanly with Ipamorelin for synergistic pulse amplification.
Why is Ipamorelin preferred over older GHRPs like GHRP-6?
Ipamorelin is highly selective for GHS-R1a and does not significantly stimulate cortisol or prolactin secretion at standard research doses. GHRP-6 and GHRP-2 activate multiple receptor types, producing cortisol and prolactin elevations that complicate interpretation of results in GH research.
Should both peptides be injected at the same time?
Yes — for maximum synergy, Ipamorelin and CJC-1295 (no-DAC) should be administered simultaneously or within minutes of each other, as the synergistic effect depends on concurrent stimulation of both GHRH and GHS-R1a receptors at the somatotroph.
What is a standard Ipamorelin/CJC research protocol duration?
Research protocols commonly run 12–24 weeks, with 2–4 week breaks between cycles to study receptor sensitivity changes. Effects on body composition and recovery markers are typically assessed at 12 and 24 week intervals.